Xanthophylls, phytosterols and pre-β1-HDL are differentially affected by fenofibrate and niacin HDL-raising in a cross-over study

Lipids

Volumn 48, Issue 12, 2013, Pages 1185-1196

  Niesor, Eric J ^a   Gauthamadasa, Kekulawalage ^b   Silva, R A Gangani D ^b   Suchankova, Gabriela ^c   Kallend, David ^c   Gylling, Helena ^d   Asztalos, Bela ^e   Damonte, Elisabetta ^f   Rossomanno, Simona ^c   Abt, Markus ^c   Davidson, W Sean ^b   Benghozi, Renee ^c  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d UNIVERSITY OF HELSINKI   (Finland)

^e TUFTS UNIVERSITY   (United States)

^f Statistics for Research Ltd   (Switzerland)

Author keywords

Antioxidant; Apolipoprotein; Cholesterol metabolism; Dyslipidemia; Fibric acid; HDL metabolism; Lipid; Lipoprotein; Phytosterol; Sterol

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; CHOLESTANOL; DESMOSTEROL; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LATHOSTEROL; NICOTINIC ACID; PHYTOSTEROL; SITOSTEROL; SQUALENE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; XANTHOPHYLL; ZEAXANTHIN;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET SUPPLEMENTATION; DRUG FORMULATION; DYSLIPIDEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTENDED DRUG RELEASE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PROTEIN BINDING; RANDOMIZED CONTROLLED TRIAL; REVERSED PHASE LIQUID CHROMATOGRAPHY; TWO DIMENSIONAL GEL ELECTROPHORESIS; YOUNG ADULT;

APOLIPOPROTEIN A-II; CROSS-OVER STUDIES; DYSLIPIDEMIAS; FEMALE; FENOFIBRATE; HIGH-DENSITY LIPOPROTEINS, PRE-BETA; HUMANS; HYPOLIPIDEMIC AGENTS; LUTEIN; MALE; MIDDLE AGED; NIACIN; PHYTOSTEROLS; XANTHOPHYLLS;

EID: 84890025193     PISSN: 00244201     EISSN: 15589307     Source Type: Journal    
DOI: 10.1007/s11745-013-3841-z     Document Type: Article

References (47)

1. Wilson PW, Abbott RD, Castelli WP (1988) High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 8:737-741
2. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B, ILLUMINATE Investigators (2007) Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357:2109-2122
3. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W (2011) Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365:2255-2267
4. Keech AR, Simes J, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M, FIELD study investigators (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366:1849-1861
5. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS, dal-OUTCOMES Investigators (2012) Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367:2089-2099
6. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ (2011) Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364:127-135
7. Besler C, Luscher TF, Landmesser U (2012) Molecular mechanisms of vascular effects of high-density lipoprotein: alterations in cardiovascular disease. EMBO Mol Med 4:251-268
8. Durrington PN, Mackness B, Mackness MI (2004) Paraoxonase polymorphisms and coronary heart disease. Lancet 364:579-580
9. Karppi J, Nurmi T, Kurl S, Rissanen TH, Nyyssonen K (2010) Lycopene, lutein and beta-carotene as determinants of LDL conjugated dienes in serum. Atherosclerosis 209:565-572
10. Navab M, Hama SY, Hough GP, Subbanagounder G, Reddy ST, Fogelman AM (2001) A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res 42:1308-1317
11. Dwyer JH, Navab M, Dwyer KM, Hassan K, Sun P, Shircore A, Hama-Levy S, Hough G, Wang X, Drake T, Merz CN, Fogelman AM (2001) Oxygenated carotenoid lutein and progression of early atherosclerosis: the Los Angeles atherosclerosis study. Circulation 103:2922-2927
12. Goulinet S, Chapman MJ (1997) Plasma LDL and HDL subspecies are heterogeneous in particle content of tocopherols and oxygenated and hydrocarbon carotenoids. Relevance to oxidative resistance and atherogenesis. Arterioscler Thromb Vasc Biol 17:786-796
13. Greene CM, Waters D, Clark RM, Contois JH, Fernandez ML (2006) Plasma LDL and HDL characteristics and carotenoid content are positively influenced by egg consumption in an elderly population. Nutr Metab (Lond) 3:6
14. Lowe GM, Bilton RF, Young AJ, Graham JM, Ford TC, Billington D (1996) Carotenoid profiles of human plasma lipoproteins. Biochem Soc Trans 24:171S
15. Connor WE, Duell B, Kean R, Wang Y (2007) The prime role of HDL to transport lutein into the retina: evidence from HDL-deficient WHAM chicks having a mutant ABCA1 transporter. Invest Ophthalmol Vis Sci 48:4226-4231
16. Mulligan JD, Flowers MT, Tebon A, Bitgood JJ, Wellington C, Hayden MR, Attie AD (2003) ABCA1 is essential for efficient basolateral cholesterol efflux during the absorption of dietary cholesterol in chickens. J Biol Chem 278:13356-13366
17. Abumrad NA, Davidson NO (2012) Role of the gut in lipid homeostasis. Physiol Rev 92:1061-1085
18. Simonen PP, Gylling H, Miettinen TA (2007) The distribution of squalene and non-cholesterol sterols in lipoproteins in type 2 diabetes. Atherosclerosis 194:222-229
19. Niesor EJ, Magg C, Ogawa N, Okamoto H, von der Mark E, Matile H, Schmid G, Clerc RG, Chaput E, Blum-Kaelin D, Huber W, Thoma R, Pflieger P, Kakutani M, Takahashi D, Dernick G, Maugeais C (2010) Modulating cholesteryl ester transfer protein activity maintains efficient pre-beta-HDL formation and increases reverse cholesterol transport. J Lipid Res 51:3443-3454
20. Niesor EJ, Chaput E, Staempfli A, Blum D, Derks M, Kallend D (2011) Effect of dalcetrapib, a CETP modulator, on non-cholesterol sterol markers of cholesterol homeostasis in healthy subjects. Atherosclerosis 219:761-767
21. Fruchart JC, Staels B, Duriez P (2001) PPARS, metabolic disease and atherosclerosis. Pharmacol Res 44:345-352
22. Kamanna VS, Kashyap ML (2008) Mechanism of action of niacin. Am J Cardiol 101(8A):20B-26B
23. Franceschini G, Favari E, Calabresi L, Simonelli S, Bondioli A, Adorni MP, Zimetti F, Gomaraschi M, Coutant K, Rossomanno S, Niesor EJ, Bernini F, Benghozi R (2013) Differential effects of established HDL-cholesterol-raising therapies on HDL quality and function in dyslipidemic patients. J Clin Lipidol [In Press]
24. Warnick GR, Albers JJ (1978) A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res 19:65-76
25. Bui MH (1994) Simple determination of retinol, alpha-tocopherol and carotenoids (lutein, all-trans-lycopene, alpha- and beta-carotenes) in human plasma by isocratic liquid chromatography. J Chromatogr B Biomed Appl 654:129-133
26. Rosales C, Gillard BK, Courtney HS, Blanco-Vaca F, Pownall HJ (2009) Apolipoprotein modulation of streptococcal serum opacity factor activity against human plasma high-density lipoproteins. Biochemistry 48:8070-8076
27. Gauthamadasa K, Rosales C, Pownall HJ, Macha S, Jerome GW, Huang R, Gangani D, Silva RA (2010) Speciated human high density lipoprotein protein proximity profiles. Biochemistry 49:10656-10665
28. Miettinen TA (1988) Cholesterol metabolism during ketoconazole treatment in man. J Lipid Res 29:43-51
29. Miettinen TA, Tilvis RS, Kesaniemi YA (1990) Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am J Epidemiol 131:20-31
30. Miida T, Miyazaki O, Nakamura Y, Hirayama S, Hanyu O, Fukamachi I, Okada M (2003) Analytical performance of a sandwich enzyme immunoassay for pre beta 1-HDL in stabilized plasma. J Lipid Res 44:645-650
31. Asztalos BF, Cupples LA, Demissie S, Horvath KV, Cox CE, Batista MC, Schaefer EJ (2004) High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 24:2181-2187
32. Asztalos BF, Batista M, Horvath KV, Cox CE, Dallal GE, Morse JS, Brown GB, Schaefer EJ (2003) Change in alpha 1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol 23:847-852
33. Johnson EJ (2010) Age-related macular degeneration and antioxidant vitamins: recent findings. Curr Opin Clin Nutr Metab Care 13:28-33
34. Vu-Dac N, Schoonjans K, Kosykh V, Dallongeville J, Fruchart JC, Staels B, Auwerx J (1995) Fibrates increase human apoA-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest 96:741-750
35. Tailleux A, Duriez P, Fruchart JC, Clavey V (2002) Apolipoprotein A-II, HDL metabolism and atherosclerosis. Atherosclerosis 164:1-13
36. Birjmohun RS, Dalinga-Thie GM, Kuivenhoven JA, Stroes ES, Otvos JD, Wareham NJ, Luben R, Kastelein JJ, Khaw KT, Boekholdt SM (2007) Apolipoprotein A-II is inversely associated with risk of future coronary artery disease. Circulation 116:2029-2035
37. Nunes VS, Leanca CC, Panzoldo NB, Parra E, Cazita PM, Nakandakare ER, de Faria EC, Quintao EC (2011) HDL-C concentration is related to markers of absorption and of cholesterol synthesis: study in subjects with low vs. high HDL-C. Clin Chim Acta 412:176-180
38. Vega GL, Weiner MF, Lipton AM, Von Bergmann K, Lutjohann D, Moore C, Svetlik D (2003) Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Arch Neurol 60:510-515
39. Matthan NR, Giovanni A, Schaefer EJ, Brown BG, Lichtenstein AH (2003) Impact of simvastatin, niacin, and/or antioxidants on cholesterol metabolism in CAD patients with low HDL. J Lipid Res 44:800-806
40. Watts GF, Barrett PH, Ji J, Serone AP, Chan DC, Croft KD, Loehrer F, Johnson AG (2003) Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes 52:803-811
41. Niesor EJ, Kallend D, Bentley D, Kees Hovingh G, Kastelein JJP, Stroes ESG (2012) Effect of dalcetrapib on non-cholesterol sterol markers of cholesterol absorption in patients with familial hypoalphalipoproteinemia or familial combined hyperlipidaemia. Eur Heart J 33:493
42. Filippatos TD, Liberopoulos EN, Kostapanos M, Gazi IF, Papavasiliou EC, Kiortsis DN, Tselepis AD, Elisaf MS (2008) The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta 1-HDL levels in obese patients with metabolic syndrome. Diabetes Obes Metab 10:476-483
43. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS, the dal-OUTCOMES Investigators (2012) Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367:2089-2099
44. Yvan-Charvet L, Kling J, Pagler T, Li H, Hubbard B, Fisher T, Sparrow CP, Taggart AK, Tall AR (2010) Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol 30:1430-1438
45. AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W (2011) Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Me 365:2255-2267
46. HPS2-THRIVE Collaborative Group (2013) HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 34:1279-1291
47. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M, FIELD study investigators (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366:1849-1861